Turn Therapeutics (TTRX) Net Cash Flow (2024 - 2026)

Turn Therapeutics' Net Cash Flow history runs 3 years deep, the most recent figure standing at $6.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 782.0% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $8.8 million (changed N/A YoY), while the FY2025 annual figure was $4.2 million, up 1463.03% from the prior year.
• Net Cash Flow was $6.2 million for Q1 2026 at Turn Therapeutics, up from $2.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $6.2 million in Q1 2026 to a low of $83819.0 in Q4 2024.
• Historically, Net Cash Flow has averaged $2.2 million across 3 years, with a median of $1.3 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 2254.3% in 2025, then soared 782.0% in 2026.
• A 3-year view of Net Cash Flow shows it stood at $83819.0 in 2024, then jumped by 2254.3% to $2.0 million in 2025, then jumped by 212.89% to $6.2 million in 2026.
• The last three Net Cash Flow figures came in at $6.2 million (Q1 2026), $2.0 million (Q4 2025), and $700034.0 (Q1 2025), per Business Quant data.